Eli Lilly and Company (LLY) Valuation — DCF & Advanced Analysis | MarketCI

Navigation

Explore Analysis Investor Relations AI Assistant Compare Screener

Help Pricing Privacy Terms

Navigation

Explore Analysis Investor Relations AI Assistant Compare Screener

Help Pricing Privacy Terms

Eli Lilly and Company (LLY) Valuation — DCF & Advanced Analysis | MarketCI | MarketCI

LLY

Market Closed

Eli Lilly and Company

NYSEHealthcare Drug Manufacturers - General

47.00K employees

CEO: David A. Ricks

Founded: 1972

$1,098.13

+$0.00(+NaN%)

Market Cap

1.03T

Beta

0.52

52W Range

N/A

Dividend Yield

0.63%

Overview Forecasts Fundamental Market Sentiment Valuation Ownership

Comprehensive Valuation

In-depth valuation analysis including DCF scenarios and peer comparisons.

AI Insight: Eli Lilly's current price exceeds the PERT-weighted fair value by 32.9%, indicating potential overvaluation supported by expert analyst targets but contradicted by DCF and EV/EBITDA metrics. Strong profitability and efficiency contrast with low growth and moderate leverage, highlighting mixed financial health. Monte Carlo analysis shows extreme volatility and high downside risk, signaling elevated investment uncertainty.

Enhanced Football Field Analysis

Loading comprehensive valuation data...

Fetching multi-methodology valuation ranges...

Explore LLY

Overview

Key metrics and AI-powered insights

Forecast

Price targets and earnings estimates

Fundamentals

Income, balance sheet and cash flow

Valuation

P/E, DCF and valuation multiples